AU752543B2 - Phenylsulfonamide-phenylethylamines useful as dopamine receptors - Google Patents
Phenylsulfonamide-phenylethylamines useful as dopamine receptors Download PDFInfo
- Publication number
- AU752543B2 AU752543B2 AU37418/99A AU3741899A AU752543B2 AU 752543 B2 AU752543 B2 AU 752543B2 AU 37418/99 A AU37418/99 A AU 37418/99A AU 3741899 A AU3741899 A AU 3741899A AU 752543 B2 AU752543 B2 AU 752543B2
- Authority
- AU
- Australia
- Prior art keywords
- ethyl
- phenyl
- propylamine
- compound
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 108050004812 Dopamine receptor Proteins 0.000 title description 2
- 102000015554 Dopamine receptor Human genes 0.000 title description 2
- GNLBKOISUOPBOL-UHFFFAOYSA-N benzenesulfonamide;2-phenylethanamine Chemical class NCCC1=CC=CC=C1.NS(=O)(=O)C1=CC=CC=C1 GNLBKOISUOPBOL-UHFFFAOYSA-N 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 61
- 150000003839 salts Chemical class 0.000 claims abstract description 12
- 102000004073 Dopamine D3 Receptors Human genes 0.000 claims abstract description 9
- 108090000525 Dopamine D3 Receptors Proteins 0.000 claims abstract description 9
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 9
- 150000002367 halogens Chemical class 0.000 claims abstract description 9
- 208000015114 central nervous system disease Diseases 0.000 claims abstract description 8
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims abstract 3
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims description 41
- WGYKZJWCGVVSQN-UHFFFAOYSA-N mono-n-propyl amine Natural products CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 claims description 23
- -1 4-methoxybenzenesulfonamido Chemical group 0.000 claims description 15
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 15
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- GCWGADZVRFZLBG-UHFFFAOYSA-N tert-butyl 2-[2-(4-aminophenyl)ethylamino]butanoate Chemical compound CC(C)(C)OC(=O)C(CC)NCCC1=CC=C(N)C=C1 GCWGADZVRFZLBG-UHFFFAOYSA-N 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- YYOHEGJBKTVTLK-UHFFFAOYSA-N 2,4-dichloro-n-[4-[2-(propylamino)ethyl]phenyl]benzenesulfonamide Chemical compound C1=CC(CCNCCC)=CC=C1NS(=O)(=O)C1=CC=C(Cl)C=C1Cl YYOHEGJBKTVTLK-UHFFFAOYSA-N 0.000 claims description 3
- GYCXCBYOHASGSD-UHFFFAOYSA-N 3-chloro-n-[3-[2-(propylamino)ethyl]phenyl]benzenesulfonamide Chemical compound CCCNCCC1=CC=CC(NS(=O)(=O)C=2C=C(Cl)C=CC=2)=C1 GYCXCBYOHASGSD-UHFFFAOYSA-N 0.000 claims description 3
- GLBXYJLKQWSMHH-UHFFFAOYSA-N 4-bromo-n-[4-[2-(propylamino)ethyl]phenyl]benzenesulfonamide Chemical compound C1=CC(CCNCCC)=CC=C1NS(=O)(=O)C1=CC=C(Br)C=C1 GLBXYJLKQWSMHH-UHFFFAOYSA-N 0.000 claims description 3
- 208000012902 Nervous system disease Diseases 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- DOFFSUIUWSPOJI-UHFFFAOYSA-N 2-chloro-4-fluoro-n-[4-[2-(propylamino)ethyl]phenyl]benzenesulfonamide Chemical compound C1=CC(CCNCCC)=CC=C1NS(=O)(=O)C1=CC=C(F)C=C1Cl DOFFSUIUWSPOJI-UHFFFAOYSA-N 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- VCHHCUQGXMWXAM-UHFFFAOYSA-N 4-chloro-n-[4-[2-(propylamino)ethyl]phenyl]benzenesulfonamide Chemical compound C1=CC(CCNCCC)=CC=C1NS(=O)(=O)C1=CC=C(Cl)C=C1 VCHHCUQGXMWXAM-UHFFFAOYSA-N 0.000 claims 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 150000002431 hydrogen Chemical group 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 3
- 101100054666 Streptomyces halstedii sch3 gene Proteins 0.000 abstract 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 44
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 18
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 15
- 239000003921 oil Substances 0.000 description 15
- 235000019198 oils Nutrition 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 13
- 239000007787 solid Substances 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 239000002904 solvent Substances 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 239000012267 brine Substances 0.000 description 7
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 7
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 201000000980 schizophrenia Diseases 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 150000003335 secondary amines Chemical class 0.000 description 4
- 208000011117 substance-related disease Diseases 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 208000018737 Parkinson disease Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 150000004982 aromatic amines Chemical class 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- UOQRWBOYRPYPAN-UHFFFAOYSA-N tert-butyl 2-[2-(3-aminophenyl)ethylamino]butanoate Chemical compound CC(C)(C)OC(=O)C(CC)NCCC1=CC=CC(N)=C1 UOQRWBOYRPYPAN-UHFFFAOYSA-N 0.000 description 3
- CYNYIHKIEHGYOZ-UHFFFAOYSA-N 1-bromopropane Chemical compound CCCBr CYNYIHKIEHGYOZ-UHFFFAOYSA-N 0.000 description 2
- PWZWTSYUZQZFKE-UHFFFAOYSA-N 2-(3-nitrophenyl)ethanol Chemical compound OCCC1=CC=CC([N+]([O-])=O)=C1 PWZWTSYUZQZFKE-UHFFFAOYSA-N 0.000 description 2
- IOXOZOPLBFXYLM-UHFFFAOYSA-N 2-(4-nitrophenyl)ethanamine Chemical compound NCCC1=CC=C([N+]([O-])=O)C=C1 IOXOZOPLBFXYLM-UHFFFAOYSA-N 0.000 description 2
- JVMHULJEYUQYSH-UHFFFAOYSA-N 2-(4-nitrophenyl)ethylazanium;chloride Chemical compound Cl.NCCC1=CC=C([N+]([O-])=O)C=C1 JVMHULJEYUQYSH-UHFFFAOYSA-N 0.000 description 2
- HKJUOMPYMPXLFS-UHFFFAOYSA-N 4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodobenzoic acid Chemical compound IC1=CC(C(=O)O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 HKJUOMPYMPXLFS-UHFFFAOYSA-N 0.000 description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
- ZLYBFBAHAQEEQQ-UHFFFAOYSA-N 4-chlorobenzenesulfonyl chloride Chemical compound ClC1=CC=C(S(Cl)(=O)=O)C=C1 ZLYBFBAHAQEEQQ-UHFFFAOYSA-N 0.000 description 2
- 241000220479 Acacia Species 0.000 description 2
- 208000017164 Chronobiology disease Diseases 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 206010013654 Drug abuse Diseases 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 206010026749 Mania Diseases 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 239000008135 aqueous vehicle Substances 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 206010013663 drug dependence Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000008024 pharmaceutical diluent Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 208000019116 sleep disease Diseases 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- UIYOVVYZPVVUMJ-UHFFFAOYSA-N tert-butyl carbamoyl carbonate Chemical compound CC(C)(C)OC(=O)OC(N)=O UIYOVVYZPVVUMJ-UHFFFAOYSA-N 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- FDTPBIKNYWQLAE-UHFFFAOYSA-N 2,4-dichlorobenzenesulfonyl chloride Chemical compound ClC1=CC=C(S(Cl)(=O)=O)C(Cl)=C1 FDTPBIKNYWQLAE-UHFFFAOYSA-N 0.000 description 1
- FCFPJKHVCHKCMP-UHFFFAOYSA-N 2-chloro-4-fluorobenzenesulfonyl chloride Chemical compound FC1=CC=C(S(Cl)(=O)=O)C(Cl)=C1 FCFPJKHVCHKCMP-UHFFFAOYSA-N 0.000 description 1
- XUAUSHRTHCVYEJ-UHFFFAOYSA-N 2-fluoro-n-[3-[2-(propylamino)ethyl]phenyl]benzenesulfonamide Chemical compound CCCNCCC1=CC=CC(NS(=O)(=O)C=2C(=CC=CC=2)F)=C1 XUAUSHRTHCVYEJ-UHFFFAOYSA-N 0.000 description 1
- ZSZKAQCISWFDCQ-UHFFFAOYSA-N 2-fluorobenzenesulfonyl chloride Chemical compound FC1=CC=CC=C1S(Cl)(=O)=O ZSZKAQCISWFDCQ-UHFFFAOYSA-N 0.000 description 1
- OINWZUJVEXUHCC-UHFFFAOYSA-N 3-chlorobenzenesulfonyl chloride Chemical compound ClC1=CC=CC(S(Cl)(=O)=O)=C1 OINWZUJVEXUHCC-UHFFFAOYSA-N 0.000 description 1
- UHCDBMIOLNKDHG-UHFFFAOYSA-N 4-(trifluoromethoxy)benzenesulfonyl chloride Chemical compound FC(F)(F)OC1=CC=C(S(Cl)(=O)=O)C=C1 UHCDBMIOLNKDHG-UHFFFAOYSA-N 0.000 description 1
- OZDCZHDOIBUGAJ-UHFFFAOYSA-N 4-(trifluoromethyl)benzenesulfonyl chloride Chemical compound FC(F)(F)C1=CC=C(S(Cl)(=O)=O)C=C1 OZDCZHDOIBUGAJ-UHFFFAOYSA-N 0.000 description 1
- GRDXCFKBQWDAJH-UHFFFAOYSA-N 4-acetamidobenzenesulfonyl chloride Chemical compound CC(=O)NC1=CC=C(S(Cl)(=O)=O)C=C1 GRDXCFKBQWDAJH-UHFFFAOYSA-N 0.000 description 1
- KMMHZIBWCXYAAH-UHFFFAOYSA-N 4-bromobenzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=C(Br)C=C1 KMMHZIBWCXYAAH-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 102000004980 Dopamine D2 Receptors Human genes 0.000 description 1
- 108090001111 Dopamine D2 Receptors Proteins 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical group CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical class NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 108010011222 cyclo(Arg-Pro) Proteins 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- WEHWNAOGRSTTBQ-UHFFFAOYSA-N dipropylamine Chemical class CCCNCCC WEHWNAOGRSTTBQ-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- GCFHZZWXZLABBL-UHFFFAOYSA-N ethanol;hexane Chemical compound CCO.CCCCCC GCFHZZWXZLABBL-UHFFFAOYSA-N 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- RZWZRACFZGVKFM-UHFFFAOYSA-N propanoyl chloride Chemical compound CCC(Cl)=O RZWZRACFZGVKFM-UHFFFAOYSA-N 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 229950001675 spiperone Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
- C07C311/46—Y being a hydrogen or a carbon atom
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8549398P | 1998-05-14 | 1998-05-14 | |
| US60/085493 | 1998-05-14 | ||
| PCT/US1999/007023 WO1999058499A1 (en) | 1998-05-14 | 1999-05-07 | Phenylsulfonamide-phenylethylamines useful as dopamine receptors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU3741899A AU3741899A (en) | 1999-11-29 |
| AU752543B2 true AU752543B2 (en) | 2002-09-19 |
Family
ID=22191975
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU37418/99A Ceased AU752543B2 (en) | 1998-05-14 | 1999-05-07 | Phenylsulfonamide-phenylethylamines useful as dopamine receptors |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US6103766A (https=) |
| EP (1) | EP1077935B1 (https=) |
| JP (1) | JP2002514623A (https=) |
| KR (1) | KR20010043546A (https=) |
| CN (1) | CN1152857C (https=) |
| AT (1) | ATE253045T1 (https=) |
| AU (1) | AU752543B2 (https=) |
| BR (1) | BR9910405A (https=) |
| CA (1) | CA2327345A1 (https=) |
| DE (1) | DE69912419T2 (https=) |
| DK (1) | DK1077935T3 (https=) |
| EA (1) | EA002918B1 (https=) |
| ES (1) | ES2211078T3 (https=) |
| HU (1) | HUP0101746A3 (https=) |
| IL (1) | IL139263A0 (https=) |
| NO (1) | NO20005732D0 (https=) |
| NZ (1) | NZ508152A (https=) |
| PL (1) | PL343891A1 (https=) |
| PT (1) | PT1077935E (https=) |
| SK (1) | SK16242000A3 (https=) |
| TR (1) | TR200003325T2 (https=) |
| TW (1) | TW450954B (https=) |
| WO (1) | WO1999058499A1 (https=) |
| ZA (1) | ZA200005921B (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU225960B1 (en) * | 1997-02-27 | 2008-01-28 | Takeda Pharmaceutical | Amine compounds, their production and use |
| EP1385495A4 (en) * | 2001-05-07 | 2005-12-21 | Smithkline Beecham Corp | SULPHONAMIDES |
| JP2004535390A (ja) * | 2001-05-07 | 2004-11-25 | スミスクライン・ビーチャム・コーポレイション | スルホンアミド |
| ATE520659T1 (de) | 2004-10-14 | 2011-09-15 | Abbott Gmbh & Co Kg | Zur behandlung von auf die modulation des dopamin-d3-rezeptors ansprechenden erkrankungen geeignete azabicycloheptylverbindungen |
| ES2364488T3 (es) | 2004-10-14 | 2011-09-05 | ABBOTT GMBH & CO. KG | Compuestos heterocíclicos adecuados para el tratamiento de trastornos que responden a la modulación del receptor de dopamina. |
| ES2380565T3 (es) * | 2004-10-14 | 2012-05-16 | Abbott Gmbh & Co. Kg | Compuestos aminoetilaromáticos adecuados para tratar trastornos que responden a la modulación del receptor de dopamina D3 |
| JP5232987B2 (ja) * | 2006-04-14 | 2013-07-10 | アボット ゲーエムベーハー ウント カンパニー カーゲー | ドーパミンｄ３受容体の調節に応答する障害の治療に好適なアリールオキシエチルアミン化合物 |
| PE20080057A1 (es) * | 2006-04-14 | 2008-03-10 | Abbott Gmbh & Co Kg | Compuestos de ariloxietilamina como agentes moduladores del receptor de dopamina d3 |
| TW200808762A (en) | 2006-04-19 | 2008-02-16 | Abbott Gmbh & Co Kg | Heterocyclic compounds suitable for treating disorders that respond to modulation of the serotonin 5HT6 receptor |
| CA2648891A1 (en) | 2006-04-19 | 2007-10-25 | Abbott Gmbh & Co. Kg | Heterocyclic arylsulphones suitable for treating disorders that respond to modulation of the serotonin 5ht6 receptor |
| WO2008026046A1 (en) * | 2006-08-30 | 2008-03-06 | Pfizer Products Inc. | Morpholine d3 dopamine antagonists |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3574741A (en) * | 1969-04-14 | 1971-04-13 | Mead Johnson & Co | Sulfonamidophenalkylamines |
| US5451677A (en) * | 1993-02-09 | 1995-09-19 | Merck & Co., Inc. | Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity |
| GB9402197D0 (en) * | 1994-02-04 | 1994-03-30 | Smithkline Beecham Plc | Compounds |
| AU4368996A (en) * | 1994-11-23 | 1996-06-17 | Neurogen Corporation | Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives; new classes of dopamine receptor subtype specific ligands |
| TR199802284T2 (xx) * | 1996-05-11 | 2000-05-22 | Smithkline Beecham P.L.C. | Dopamin D3 resept�rlerinin mod�lat�rleri olarak tetrahidroizokuinolin t�revleri. |
| WO1998003473A1 (en) * | 1996-07-22 | 1998-01-29 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
| JPH1180156A (ja) * | 1997-09-04 | 1999-03-26 | Hokuriku Seiyaku Co Ltd | １−（置換アリール）アルキル−１ｈ−イミダゾピリジン−４−アミン誘導体 |
-
1999
- 1999-04-26 TW TW088106644A patent/TW450954B/zh not_active IP Right Cessation
- 1999-05-07 US US09/306,748 patent/US6103766A/en not_active Expired - Fee Related
- 1999-05-07 JP JP2000548303A patent/JP2002514623A/ja not_active Withdrawn
- 1999-05-07 SK SK1624-2000A patent/SK16242000A3/sk unknown
- 1999-05-07 EP EP99919771A patent/EP1077935B1/en not_active Expired - Lifetime
- 1999-05-07 PT PT99919771T patent/PT1077935E/pt unknown
- 1999-05-07 AT AT99919771T patent/ATE253045T1/de not_active IP Right Cessation
- 1999-05-07 PL PL99343891A patent/PL343891A1/xx unknown
- 1999-05-07 WO PCT/US1999/007023 patent/WO1999058499A1/en not_active Ceased
- 1999-05-07 DE DE69912419T patent/DE69912419T2/de not_active Expired - Fee Related
- 1999-05-07 NZ NZ508152A patent/NZ508152A/xx unknown
- 1999-05-07 DK DK99919771T patent/DK1077935T3/da active
- 1999-05-07 AU AU37418/99A patent/AU752543B2/en not_active Ceased
- 1999-05-07 BR BR9910405-9A patent/BR9910405A/pt not_active Application Discontinuation
- 1999-05-07 CN CNB998052175A patent/CN1152857C/zh not_active Expired - Fee Related
- 1999-05-07 EA EA200001184A patent/EA002918B1/ru not_active IP Right Cessation
- 1999-05-07 HU HU0101746A patent/HUP0101746A3/hu unknown
- 1999-05-07 ES ES99919771T patent/ES2211078T3/es not_active Expired - Lifetime
- 1999-05-07 IL IL13926399A patent/IL139263A0/xx not_active IP Right Cessation
- 1999-05-07 TR TR2000/03325T patent/TR200003325T2/xx unknown
- 1999-05-07 CA CA002327345A patent/CA2327345A1/en not_active Abandoned
- 1999-05-07 KR KR1020007012661A patent/KR20010043546A/ko not_active Abandoned
-
2000
- 2000-10-23 ZA ZA200005921A patent/ZA200005921B/en unknown
- 2000-11-13 NO NO20005732A patent/NO20005732D0/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NO20005732L (no) | 2000-11-13 |
| CN1152857C (zh) | 2004-06-09 |
| PT1077935E (pt) | 2004-03-31 |
| NZ508152A (en) | 2003-03-28 |
| BR9910405A (pt) | 2001-01-09 |
| CN1297431A (zh) | 2001-05-30 |
| DE69912419T2 (de) | 2004-07-22 |
| AU3741899A (en) | 1999-11-29 |
| PL343891A1 (en) | 2001-09-10 |
| DE69912419D1 (de) | 2003-12-04 |
| HK1036049A1 (en) | 2001-12-21 |
| EP1077935B1 (en) | 2003-10-29 |
| ZA200005921B (en) | 2001-11-14 |
| KR20010043546A (ko) | 2001-05-25 |
| ES2211078T3 (es) | 2004-07-01 |
| WO1999058499A1 (en) | 1999-11-18 |
| JP2002514623A (ja) | 2002-05-21 |
| TR200003325T2 (tr) | 2001-04-20 |
| DK1077935T3 (da) | 2004-02-16 |
| US6103766A (en) | 2000-08-15 |
| NO20005732D0 (no) | 2000-11-13 |
| EA200001184A1 (ru) | 2001-04-23 |
| TW450954B (en) | 2001-08-21 |
| EP1077935A1 (en) | 2001-02-28 |
| CA2327345A1 (en) | 1999-11-18 |
| IL139263A0 (en) | 2001-11-25 |
| EA002918B1 (ru) | 2002-10-31 |
| HUP0101746A2 (hu) | 2002-03-28 |
| HUP0101746A3 (en) | 2002-10-28 |
| ATE253045T1 (de) | 2003-11-15 |
| SK16242000A3 (sk) | 2001-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL166582B1 (pl) | Sposób wytwarzania nowych pochodnych amin aromatycznych PL PL | |
| KR0183374B1 (ko) | 혈관평활근 이완작용을 가진 화합물과 그의 제조방법 | |
| CN1311773A (zh) | 神经肽y5受体拮抗剂 | |
| AU752543B2 (en) | Phenylsulfonamide-phenylethylamines useful as dopamine receptors | |
| EP1567492B1 (en) | N-arylsulfonyl-3-aminoalkoxyindoles | |
| US4980365A (en) | N-substituted-5,6-dimethoxy-1,2-benzisoxazole-3-propanamine and related compounds as analgesic and hypotensive agents | |
| MXPA02009697A (es) | Compuestos de eter difenilico utiles en terapia. | |
| JPS60239458A (ja) | 新規化合物およびそれを含有する抗不整脈剤医薬組成物 | |
| EP0594001B1 (en) | Pyrazolo 4,3-c pyridines, a process for their preparation and their use as serotonin reuptake inhibitors | |
| WO1989005806A1 (en) | Novel antiarrhythmic agents iii | |
| CN103781771A (zh) | 苯并噻唑酮化合物 | |
| JP2008509962A (ja) | ５−ｈｔ７受容体アンタゴニスト | |
| JP2008509961A (ja) | ５−ｈｔ７受容体アンタゴニスト | |
| US4567181A (en) | Bicyclo (4.2.0) 1,3,5-octatriene compounds and use as α-adrenergics | |
| US5472966A (en) | Antidepressant heteroarylaminoalkyl derivatives of naphthyl-monazines | |
| BRPI0608523A2 (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos para inibir receptor de histamina h3 em um mamìfero, para tratar ou prevenir um distúrbio do sistema nervoso, para tratar ou prevenir obesidade e para tratar ou prevenir um distúrbio ou doença, e, uso de um composto ou um sal do mesmo | |
| MXPA01008860A (es) | Derivados de fenoxifenilheterociclilo como inhibidores selectivos de la recaptacion de serotonina. | |
| MXPA00011147A (en) | Phenylsulfonamide-phenylethylamines useful as dopamine receptors | |
| CZ20004173A3 (cs) | Fenylsulfonamid-fenylethylaminy užitečné jako dopaminové receptory | |
| US20040019064A1 (en) | Pyridopyrimidine derivatives as 5-HT6 antagonists | |
| HK1036049B (en) | Phenylsulfonamide-phenylethylamines useful as dopamine receptors | |
| JP2004123649A (ja) | 新規環状アミド誘導体 | |
| BR122024013557B1 (pt) | Processos para preparar um composto | |
| KR100922486B1 (ko) | 비만, 제 ⅱ 형 당뇨병 및 ｃｎｓ 장애의 치료를 위한신규한 아릴술폰아미드 화합물 | |
| BR122024013536B1 (pt) | Processo para preparar um composto |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |